LSD was originally developed as a psychiatric tool, and after decades of prohibition, it is being studied again for treating anxiety, depression, and cluster headaches. The drug has no approved medical use today, but an LSD-based medication called MM-120 has received FDA Breakthrough Therapy designation for generalized anxiety disorder, putting it on a fast track toward potential approval.
How LSD Works in the Brain
LSD acts primarily on serotonin receptors, with the 5-HT2A receptor playing the central role. When LSD binds to this receptor, it reshapes how different brain regions communicate with each other. Sensory areas become more interconnected, while the parts of the brain responsible for higher-order thinking, planning, and self-referential thought become less tightly linked. The stronger this sensory boost, the more pronounced the loosening of associative networks, creating a tightly correlated seesaw effect between the two.
This rewiring is temporary during a single dose, but the psychological shifts it produces can persist well beyond the drug’s active window. That lasting impact is what makes LSD interesting to researchers studying conditions rooted in rigid thought patterns, like treatment-resistant anxiety and depression.
Original Psychiatric Uses in the 1950s and 1960s
Sandoz Pharmaceuticals marketed LSD under the brand name Delysid starting in the 1950s and distributed it to researchers and clinicians. During this period, psychiatrists used it as an adjunct to psychotherapy, a direct antidepressant, a tool for studying the chemical origins of mental illness, and even as a way to model psychosis in research settings. Thousands of papers were published on its psychiatric applications before governments began restricting it in the late 1960s, effectively halting research for decades.
Anxiety and Depression
The most advanced modern research centers on anxiety. A phase II clinical trial published in Biological Psychiatry tested two sessions of 200 micrograms of LSD against placebo in 42 patients with generalized anxiety, including some with life-threatening illnesses. Patients who received LSD showed significant reductions in anxiety that persisted for at least 16 weeks after their last session. The effect size was large, with depression scores dropping substantially on two separate rating scales as well.
These results led the FDA to grant Breakthrough Therapy designation to MM-120, a pharmaceutical-grade LSD formulation developed by MindMed. That designation doesn’t mean the drug is approved. It means the FDA considers the early evidence promising enough to accelerate the review process. Phase III trials are underway.
Cluster Headaches
People with cluster headaches, sometimes called “suicide headaches” because of their severity, have reported for years that LSD can break a cluster cycle. Formal research is catching up. A clinical trial currently recruiting patients is testing whether seven low doses of LSD (25 micrograms each, given every three days over three weeks) can reduce weekly attack frequency, duration, and severity in people with chronic cluster headaches. Results aren’t available yet, but the trial’s design reflects growing institutional interest in what was previously only anecdotal evidence.
Microdosing: Hype vs. Evidence
Microdosing involves taking roughly one-tenth of a full dose, typically 7 to 20 micrograms, on a regular schedule. Proponents claim it enhances creativity, mood, and focus without producing any perceptual effects. The practice has become popular in tech and wellness circles.
The best evidence so far is discouraging. A large self-blinding study published in eLife had participants randomly assign themselves to microdoses or placebos without knowing which they received. Both groups reported improvements in mood, creativity, and energy. When researchers compared the two groups, there were no meaningful differences. The small effects that did emerge could be explained by participants correctly guessing whether they had taken the real dose. The researchers concluded that the reported benefits of microdosing are likely driven by the placebo effect and psychological expectation rather than the drug itself.
How Doses Compare
The range of LSD doses spans a wide spectrum, and the effects at each level are dramatically different. As little as 25 micrograms can produce noticeable psychoactive effects. Clinical trials for anxiety have used 200 micrograms per session, while the cluster headache trial uses just 25. Street doses today typically contain 20 to 80 micrograms, significantly less potent than what circulated in the 1960s and 1970s, when a single dose often contained 100 to 200 micrograms or more.
Addiction Potential and Safety
LSD does not cause physical dependence. Controlled studies have found no evidence of withdrawal symptoms or the compulsive drug-seeking behavior characteristic of addictive substances. Tolerance builds rapidly, meaning taking the same dose on consecutive days produces diminishing effects, which actually discourages frequent use.
The primary risks are psychological. A difficult experience during a trip can cause significant distress, and in rare cases, people develop hallucinogen persisting perception disorder (HPPD), a condition where visual distortions experienced during the trip continue to occur months or even years after the last use. HPPD is considered rare, but it can be distressing enough to interfere with daily life. Diagnosis requires ruling out other causes of visual disturbances, and the perceptual symptoms must be clearly linked to prior hallucinogen use.
LSD has a wide margin of physical safety, with no confirmed lethal dose in humans from the drug alone. The dangers lie almost entirely in behavior during intoxication and in the psychological aftermath for vulnerable individuals.
Current Legal Status
LSD remains a Schedule I controlled substance in the United States, meaning it is illegal to manufacture, possess, or distribute outside of approved research settings. The FDA’s Breakthrough Therapy designation for MM-120 does not change its legal status for general use. If phase III trials succeed, MM-120 could eventually become available as a prescription treatment administered in clinical settings, but that outcome is still years away.